Related references
Note: Only part of the references are listed.Olaparib for the treatment of epithelial ovarian cancer
Jennifer McLachlan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues
Eliana Bignotti et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhenfeng Zhang et al.
THERANOSTICS (2016)
Complex Breakpoints and Template Switching Associated with Non-canonical Termination of Homologous Recombination in Mammalian Cells
Andrea J. Hartlerode et al.
PLOS GENETICS (2016)
In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer
Yi Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Downregulation of MACC1 expression enhances cisplatin sensitivity in SKOV-3/DDP cells
Z. M. Chen et al.
GENETICS AND MOLECULAR RESEARCH (2015)
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin TOP2A as marker of response to PLD in ovarian cancer
J. Erriquez et al.
GYNECOLOGIC ONCOLOGY (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression
Carter J. Barger et al.
ONCOTARGET (2015)
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Liu Yang et al.
ONCOTARGET (2015)
Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
Nicoletta Colombo
EJC SUPPLEMENTS (2015)
FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells
Wen-Tai Chiu et al.
ONCOTARGET (2015)
Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma
Niloofar N. Nik et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance
Stefania Zona et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2014)
Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer
Jia Li et al.
BMB REPORTS (2014)
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Aki Miyasaka et al.
BMC CANCER (2014)
Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy
Alvaro Aytes et al.
CANCER CELL (2014)
Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells
Sahiti Chukkapalli et al.
EXPERIMENTAL CELL RESEARCH (2014)
CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
Margaret Gil et al.
JOURNAL OF IMMUNOLOGY (2014)
Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer
Ning Wen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma
Huimin Shen et al.
MEDICAL ONCOLOGY (2014)
FOXM1 Modulates Cisplatin Sensitivity by Regulating EXO1 in Ovarian Cancer
Jinhua Zhou et al.
PLOS ONE (2014)
Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance
Fung Zhao et al.
PLOS ONE (2014)
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
D. S. P. Tan et al.
BRITISH JOURNAL OF CANCER (2013)
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer
Tarek Abdel-Fatah et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
Britta Stordal et al.
MOLECULAR ONCOLOGY (2013)
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Theresa A. Lawrie et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage
Marianna Halasi et al.
PLOS ONE (2012)
Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
David W. Chan et al.
PLOS ONE (2012)
Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance
Fung Zhao et al.
Frontiers of Medicine (2012)
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27
Hiroaki Itamochi et al.
GYNECOLOGIC ONCOLOGY (2011)
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Significance of Cell Cycle Regulatory Proteins as Malignant and Prognostic Biomarkers in Ovarian Epithelial Tumors
Yoon Hee Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells
Gabriel T. M. Lok et al.
PLOS ONE (2011)
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Robert J. Kurman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma
Ahmad Waseem et al.
ORAL ONCOLOGY (2010)
FOXM1 Upregulation Is an Early Event in Human Squamous Cell Carcinoma and it Is Enhanced by Nicotine during Malignant Transformation
Emilios Gemenetzidis et al.
PLOS ONE (2009)
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
Richard W. Tothill et al.
CLINICAL CANCER RESEARCH (2008)
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2008)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Koebel et al.
PLOS MEDICINE (2008)
Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes
Yongjun Tan et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy
Eliana Bignotti et al.
GYNECOLOGIC ONCOLOGY (2006)
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
K. Gudmundsdottir et al.
ONCOGENE (2006)
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
N Ishimura et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
BRCA1 regulates gene expression for orderly mitotic progression
I Bae et al.
CELL CYCLE (2005)
Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data
C Pilarsky et al.
NEOPLASIA (2004)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)